Ad
related to: rituximab survival ratevyvgarthcp.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
A phase II clinical trial has found that the treatment of SMZL with a combination of rituximab plus bemdamustine achieves overall response and complete response rates of 91% and 73%, respectively, with percentage responses enduring for >3 years, progression-free survival rate, and overall survival rate of 93%, 90%, and 96%, respectively.
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Survival rates for most childhood cancers have improved, with a notable improvement in acute lymphoblastic leukemia (the most common childhood cancer). Due to improved treatment, the 5-year survival rate for acute lymphoblastic leukemia has increased from less than 10% in the 1960s to about 90% during the time period 2003-2009.
Adding rituximab, a monoclonal antibody targeting the CD20 B-cell antigen, to the CHOP regimen has been shown to improve complete-response rates and extend event-free and overall survival in elderly patients without significantly increasing toxicity. [7] In metastatic breast cancer overexpressing HER2, chemoimmunotherapy also shows better ...
The modified CHOP chemoimmunotherapy regimen termed [R]-CHOEP, which consists of rituximab (an immunotherapy antibody preparation that binds to CD20 cell surface protein), cyclophosphamide, doxorubicin, vincristine, and prednisone, has given overall response rates of 50–60% with median overall survival times of 15–21 months. Other ...
median overall survival time of approximately 12–16 months, with five-year survival rate of approximately 26% and the long-term survival rate of approximately 4 - 5%. Limited-stage small cell lung carcinoma (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which is small enough to be encompassed within a ...
The mean response rate for new cancer drugs approved by the U.S. Food and Drug Administration, expressed as relative risk, ranges between 1.38x [3] and 2.37x. [4]
High-dose chemotherapy (HDC) is a regimen of chemotherapy medicines given at larger dosages. This therapeutic strategy is used to treat some cancers, especially those that are aggressive or have a high chance of coming back. With increased doses of chemotherapy chemicals administered to the body, HDC seeks to optimize the death of cancer cells.
Ad
related to: rituximab survival ratevyvgarthcp.com has been visited by 10K+ users in the past month